July, 2024

article thumbnail

UK’s antibiotic subscription funding model – a route to market sustainability?

Pharmaceutical Technology

On 8 May, the UK was the world's first government to formally implement a new model for the funding and support of novel antibiotic commercialisation.

Marketing 299
article thumbnail

Artiva prices $167M IPO, riding optimism for autoimmune cell therapy

Bio Pharma Dive

The offering comes days after the publication of a paper showing what analysts said was early proof that “off-the-shelf” cell therapies can treat inflammatory diseases.

326
326
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

July 23, 2024: Article From Ethics and Regulatory Core Highlights Key Challenges for Pragmatic Trials

Rethinking Clinical Trials

In an invited commentary published this month in Circulation: Cardiovascular Quality and Outcomes , authors from the NIH Pragmatic Trials Collaboratory’s Ethics and Regulatory Core describe the recurring and emerging ethical issues in pragmatic clinical trials. Coauthors Caleigh Propes, Stephanie Morain, and Pearl O’Rourke discuss 3 key challenges facing pragmatic trials researchers: waivers and alterations of informed consent and their implications for transparency managing and resp

Trials 313
article thumbnail

Amgen, BMS and Merck have the most exposure as Big Pharma eyes $183B patent cliff: analyst

Fierce Pharma

While patent cliffs are looming for many of biopharma’s top-selling products, the industry has enormous capacity to respond as “conditions for M&A are favorable,” according to a research note f | While patent cliffs loom for many of biopharma’s top-selling products, the industry has enormous capacity to respond as “conditions for M&A are favorable,” according to a July 11 research note from Morgan Stanley.

article thumbnail

Bridging Innovation & Patient Care: The Growing Role of AI

Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

article thumbnail

Why Is Antimicrobial Resistance Not Getting Much Attention from Biopharma?

BioSpace

Investment in the development of new antimicrobials is falling rapidly, even as the global public health threat of antimicrobial resistance is growing increasingly severe worldwide.

article thumbnail

One Diet Choice While Pregnant May Protect Your Child’s Heart For Life

AuroBlog - Aurous Healthcare Clinical Trials blog

The food consumed by a pregnant mother just got a little bit more important. According to a new study on pregnant mice, a diet rich in fiber improves the long-term heart health of developing offspring, significantly lowering their risk of cardiovascular disease later in life.

More Trending

article thumbnail

Pfizer quits Duchenne gene therapy, lays off staff following study setback

Bio Pharma Dive

The company is letting go of 150 staffers alongside a decision to officially terminate the high-profile program, which was acquired in 2016.

article thumbnail

WorldwideEdge: Driving Innovation in Bioanalytical Lab Run Success Rates

Worldwide Clinical Trials

At Worldwide Clinical Trials’ bioanalytical lab, we view challenges as opportunities to excel and set new standards. The path to drug approval is complex, with many variables and potential delays. That’s why our team is committed to continuous improvement through our initiative, WorldwideEdge, where we optimize everything from our processes to our teams’ performance for each drug development program.

article thumbnail

July 10, 2024: Asking Different Causal Questions in Randomized Trials, in This Week’s PCT Grand Rounds

Rethinking Clinical Trials

Dr. Miguel Hernán In this Friday’s PCT Grand Rounds, Miguel Hernán of Harvard University will present “Causal Estimands: Should We Ask Different Causal Questions in Randomized Trials and in the Observational Studies That Emulate Them?” The Grand Rounds session will be held on Friday, July 12, 2024, at 1:00 pm eastern. Hernán is the Kolokotrones Professor of Biostatistics and Epidemiology and the director of the CAUSALab at Harvard T.H.

Trials 176
article thumbnail

Study suggests targeting amyloid beta production could be promising in AD

Pharma Times

The neurodegenerative disease is currently the most common cause of dementia

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Does a Shot of Olive Oil Really Prevent Hangovers? Here’s The Science.

AuroBlog - Aurous Healthcare Clinical Trials blog

The search for alcohol hangover cures is as old as alcohol itself. Many cures and remedies are sold, but scientific evidence for their effectiveness is lacking. Recently, the notion that taking a shot of olive oil before consuming alcohol can prevent hangovers has garnered attention.

article thumbnail

EMA fast-tracks review of AstraZeneca’s sipavibart to stop Covid

Pharmaceutical Technology

The EMA has accepted AstraZeneca's MAA for sipavibart as Covid-19 pre-exposure prophylaxis (prevention) in immunocompromised patients.

290
290
article thumbnail

Lilly drug for Alzheimer’s approved by FDA

Bio Pharma Dive

The drug, which Lilly will sell as Kinsunla, carries a warning for the risk of a certain kind of imaging abnormality that can be serious in rare cases.

Drugs 338
article thumbnail

Type 2 Diabetes: Challenges & Emergent Strategies for Clinical Research

Worldwide Clinical Trials

With advancements in technology and a deeper understanding of type 2 diabetes (T2D), therapeutics, such as GLP-1 agonists and continuous glucose monitors (CGM), have significantly improved care options for patients with T2D. Despite these advancements, challenges for widespread effective care remain due to the heterogeneous patient population, opening the door for further development of treatments for T2D.

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

July 24, 2024: In This Week’s PCT Grand Rounds, Fonarow to Discuss Interventions for Optimizing Guideline-Directed Medical Therapy

Rethinking Clinical Trials

In this Friday’s PCT Grand Rounds, Gregg Fonarow of the University of California, Los Angeles, will present “Interventions for Optimization of Guideline-Directed Medical Therapy.” The Grand Rounds session will be held on Friday, July 26, 2024, at 1:00 pm eastern. Fonarow is the Eliot Corday Professor of Cardiovascular Medicine and Science at UCLA, director of the Ahmanson-UCLA Cardiomyopathy Center, and codirector of the UCLA Preventative Cardiology Program.

article thumbnail

UK DRI and NHS collaborate on digitally enabled dementia care platform

Pharma Times

Around one in five dementia hospitalisations are due to potentially preventable causes

Research 167
article thumbnail

Breakthrough Test Predicts Whether Organ Transplants Will Be Rejected

AuroBlog - Aurous Healthcare Clinical Trials blog

Scientists have figured out a non-invasive way to determine if a transplanted organ is failing to take in a patient – no matter if it’s a kidney, liver, lung, or heart.

Scientist 246
article thumbnail

FDA launches new rare disease innovation hub

Pharmaceutical Technology

The new hub will act as a central point of connection and engagement for the rare disease community for FDA-related concerns.

278
278
article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

10 clinical trials to watch in the second half of 2024

Bio Pharma Dive

Study results are expected for a pair of closely watched obesity drugs, while key tests await for a high-priced AbbVie acquisition and one of 2023’s largest IPOs.

article thumbnail

CDMOs: Shaping The Future of Pharmaceutical Innovation

Pharma Mirror

The pharmaceutical industry is constantly shifting, as consumers seek the best treatments. As the market demands new solutions, drugmakers are tasked with investing heavily in research, development, manufacturing and commercialization. Meeting the needs of the sector can be challenging, especially for companies that don’t have the necessary resources.

article thumbnail

July 31, 2024: Gene Editing Therapies and Population Health, in This Week’s PCT Grand Rounds

Rethinking Clinical Trials

Dr. Adrian Hernandez In this Friday’s PCT Grand Rounds, Adrian Hernandez of Duke University will present “Precision Health to Population Health: Opportunities and Challenges for Gene Editing Therapies.” The Grand Rounds session will be held on Friday, August 2, 2024, at 1:00 pm eastern. Hernandez is a professor of medicine and vice dean in the Duke University School of Medicine and the executive director of the Duke Clinical Research Institute.

article thumbnail

Glasgow scientists develop first bone marrow model to support human stem cells

Pharma Times

LT-HSCs replenish blood cells after treatment for blood cancers, such as leukaemia

Scientist 153
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Eyelash Extensions Can Be Seriously Dangerous, Expert Warns

AuroBlog - Aurous Healthcare Clinical Trials blog

Ultra long, thick eyelashes might be in vogue but are they worth the expense – and the risk to health? Our natural eyelashes perform important functions. The eye is exposed to the elements so it’s a window for bacteria and viruses to enter the body – potentially causing death.

Bacteria 246
article thumbnail

NHS rolls out “more convenient” Ocrevus injection for multiple sclerosis

Pharmaceutical Technology

The subcutaneous formulation of Roche’s blockbuster Ocrevus will cut hospital treatment time for patients.

279
279
article thumbnail

Revolution Medicines firms up Phase 3 trial plans with latest cancer drug data

Bio Pharma Dive

Updated results show the biotech's RAS inhibitor shrank pancreatic tumors in 20% to 25% of study participants, but with high rates of side effects like rash and nausea.

Medicine 319
article thumbnail

Pfizer thinks it found its obesity pill

Bio Pharma Dive

Far behind companies like Novo and Eli Lilly, Pfizer hopes the version of the drug, danuglipron, that it’s chosen to advance can break into the ultra-lucrative market for weight-loss medicines.

Medicine 315
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Cartesian data add to progress, questions for CAR-T in autoimmune disease

Bio Pharma Dive

The company claimed Phase 2 study results prove the therapy’s promise treating myasthenia gravis. But shares lost more than a quarter of their value amid questions about the data.

315
315
article thumbnail

5 FDA decisions to watch in the third quarter

Bio Pharma Dive

Multibillion-dollar buyouts from Bristol Myers Squibb and Gilead could yield new drugs for brain and liver diseases, while a new cell therapy may reach market.

Marketing 315
article thumbnail

Obesity pill from Roche shows promising weight loss in small study

Bio Pharma Dive

Treatment led to "clinically meaningful" weight loss over four weeks, but longer studies will be needed to compare it to Wegovy and Zepbound.

303
303
article thumbnail

Pfizer research chief Dolsten to step down, with company at a crossroads

Bio Pharma Dive

The company has begun searching for a successor to Dolsten, who oversaw more than 35 drug and vaccine approvals but also some notable setbacks during his time as Pfizer’s top scientist.

Scientist 304
article thumbnail

2022 Research: The Rapid Rise of Ocean Freight Visibility

A research study conducted by The Journal of Commerce and FourKites surveyed hundreds of international shippers, exploring how their usage of global supply chain visibility technology has evolved since the onset of global disruptions caused by COVID-19. For international shippers, ocean freight visibility has evolved from optional to essential and satisfaction with visibility varies greatly depending on how it is obtained and delivered.